Incidence and management of bevacizumab-associated gastrointestinal perforations in patients with recurrent ovarian carcinoma

John P. Diaz; William P. Tew; Oliver Zivanovic; Jason Konner; Paul J. Sabbatini; Lisa A. dos Santos; Nadeem R. Abu-Rustum; Dennis S. Chi; Carol Aghajanian; Richard R. Barakat

doi:10.1016/j.ygyno.2009.11.017

Incidence and management of bevacizumab-associated gastrointestinal perforations in patients with recurrent ovarian carcinoma

John P. Diaz, William P. Tew, Oliver Zivanovic, Jason Konner, Paul J. Sabbatini, Lisa A. dos Santos, Nadeem R. Abu-Rustum, Dennis S. Chi, Carol Aghajanian, Richard R. Barakat

Miami Cancer Institute

Research output: Contribution to journal › Article › peer-review

Original language	American English
Journal	Gynecologic Oncology
Volume	116
DOIs	https://doi.org/10.1016/j.ygyno.2009.11.017
State	Published - Mar 1 2010

Disciplines

Medicine and Health Sciences
Surgery
Obstetrics and Gynecology

Access to Document

10.1016/j.ygyno.2009.11.017License: Unspecified

Cite this

@article{49c6bcf664bc4665a27cc17acc533de7,

title = "Incidence and management of bevacizumab-associated gastrointestinal perforations in patients with recurrent ovarian carcinoma",

author = "Diaz, {John P.} and Tew, {William P.} and Oliver Zivanovic and Jason Konner and Sabbatini, {Paul J.} and Santos, {Lisa A. dos} and Abu-Rustum, {Nadeem R.} and Chi, {Dennis S.} and Carol Aghajanian and Barakat, {Richard R.}",

note = "Six (4%) of 160 patients with ovarian carcinoma who had been treated with bevacizumab developed GI perforations, with a median of 4 (range, 2-8) previous cytotoxic regimens. The median serum CA-125 at the start of treatment was 228 U/mL (range, 50-3106 U/mL). The median number of bevacizumab cycles prior to perforation was 10.5 (range, 2-20).",

year = "2010",

month = mar,

day = "1",

doi = "10.1016/j.ygyno.2009.11.017",

language = "American English",

volume = "116",

journal = "Gynecologic Oncology",

}

TY - JOUR

T1 - Incidence and management of bevacizumab-associated gastrointestinal perforations in patients with recurrent ovarian carcinoma

AU - Diaz, John P.

AU - Tew, William P.

AU - Zivanovic, Oliver

AU - Konner, Jason

AU - Sabbatini, Paul J.

AU - Santos, Lisa A. dos

AU - Abu-Rustum, Nadeem R.

AU - Chi, Dennis S.

AU - Aghajanian, Carol

AU - Barakat, Richard R.

N1 - Six (4%) of 160 patients with ovarian carcinoma who had been treated with bevacizumab developed GI perforations, with a median of 4 (range, 2-8) previous cytotoxic regimens. The median serum CA-125 at the start of treatment was 228 U/mL (range, 50-3106 U/mL). The median number of bevacizumab cycles prior to perforation was 10.5 (range, 2-20).

PY - 2010/3/1

Y1 - 2010/3/1

UR - https://www.sciencedirect.com/science/article/pii/S0090825809009585

U2 - 10.1016/j.ygyno.2009.11.017

DO - 10.1016/j.ygyno.2009.11.017

M3 - Article

VL - 116

JO - Gynecologic Oncology

JF - Gynecologic Oncology

ER -

Incidence and management of bevacizumab-associated gastrointestinal perforations in patients with recurrent ovarian carcinoma

Disciplines

Access to Document

Other files and links

Cite this